Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications

Carl C. Ward[1,2], Jordan I. Kleinman[1,2], Clive Yik Sham Chung[1,2], Kenneth Kim[3,6], Yana Petri[1,2], Patrick S. Lee[2,4], Jason R. Thomas[2,5,6], John A. Tallarico[2,5], Jeffrey M. McKenna[2,5], Markus Schirle[2,5], and Daniel K. Nomura[1,2,3,7] *

[1] Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720

[2] Novartis-Berkeley Center for Proteomics and Chemistry Technologies

[3] Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720

[4] Novartis Institutes for BioMedical Research, Emeryville, CA 94608

[5] Novartis Institutes for BioMedical Research, Cambridge, MA 02139

[6] Current address: Vertex Pharmaceuticals, Boston, MA 02210

[7] Department of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, CA 94720

*correspondence to dnomura@berkeley.edu

Keywords: chemoproteomics, RNF4, targeted protein degradation, degraders, covalent ligand

Abstract

Targeted protein degradation has arisen as a powerful strategy for drug discovery allowing the targeting of undruggable proteins for proteasomal degradation. This approach most often employs heterobifunctional degraders consisting of a protein-targeting ligand linked to an E3 ligase recruiter to ubiquitinate and mark proteins of interest for proteasomal degradation. One challenge with this approach, however, is that only few E3 ligase recruiters currently exist for targeted protein degradation applications, despite the hundreds of known E3 ligases in the human genome. Here, we utilized activity-based protein profiling (ABPP)-based covalent ligand screening approaches to identify cysteine-reactive small-molecules that react with the E3 ubiquitin ligase RNF4 and provide chemical starting points for the design of RNF4-based degraders. The hit covalent ligand from this screen reacted with one of two zinc-coordinating cysteines in the RING domain, C132 and C135, with no effect on RNF4 activity. We further optimized the potency of this hit and incorporated this potential RNF4 recruiter into a bifunctional degrader linked to JQ1, an inhibitor of the BET family of bromodomain proteins. We demonstrate that the resulting compound CCW 28-3 is capable of degrading BRD4 in a proteasome- and RNF4-dependent manner. In this study, we have shown the feasibility of using chemoproteomics-enabled covalent ligand screening platforms to expand the scope of E3 ligase recruiters that can be exploited for targeted protein degradation applications.

Main text

Targeted protein degradation is a groundbreaking drug discovery approach for tackling the undruggable proteome by exploiting the cellular protein degradation machinery to selectively eliminate target proteins [1,2]. This technology most often involves the utilization of heterobifunctional degrader molecules consisting of a substrate-targeting ligand linked to an E3 ligase recruiter. These degraders are capable of recruiting E3 ligases to specific protein targets to ubiquitinate and mark targets for degradation in a proteasome-dependent manner. As functional inhibition of the target is not necessary for degrader efficacy, this strategy has the potential to target and degrade any protein in the proteome for which there exists a ligand. However, a major challenge in the application of this technology is relatively small number of E3 ligase recruiters. While there are ~600 different E3 ligases, there are only a few E3 ligases that have been successfully exploited in suhc a strategy , including small-molecule recruiters for cereblon, VHL, MDM2, and cIAP [2,3]. Identifying facile strategies for discovering ligands that bind to E3 ligases remains crucial for expanding the set of E3 ligase recruiters that can be utilized for targeted protein degradation applications.

Activity-based protein profiling (ABPP) has arisen as a powerful platform for ligand discovery against targets of interest, including proteins commonly considered as undruggable [4–10]. ABPP utilizes reactivity-based chemical probes to map proteome-wide reactive and ligandable hotspots directly in complex biological systems [11,12]. When used in a competitive manner, covalently-acting small-molecule librarie can be screened for competition against the binding of reactivity-based probes to facilitate covalent ligand discovery against proteins of interest [4–7,9,13–15]. Towards discovering covalent ligands that may react with E3 ubiquitin ligases, we first investigated whether representative commercially available E3 ligases--MDM2, RNF4, and UBE3A--could be labeled by the cysteine-reactive tetramethylrhodamine-5-iodoacetamide dihydroiodide (IA-rhodamine) reactivity-based probe. We observed IA-rhodamine labeling of all three E3 ligases in a dose-responsive manner **(Fig. 1A)**. While previous studies have already uncovered MDM2 and UBE3A small-molecule modulators [16–18], no chemical tools exist for the E3 ubiquitin ligase RNF4, which recognizes SUMOylated proteins and ubiquitinates these proteins for subsequent proteasomal degradation [19,20]. We thus focused our efforts on developing a potential E3 ligase recruiter for RNF4.

In search of RNF4-targeting ligands, we screened a cysteine-reactive covalent ligand library against IA-rhodamine labeling of pure human RNF4 using gel-based ABPP **(Fig. 1B; Table S1)**. We identified several

potential hits from this screen, including TRH 1-74, YP 1-44, DKM 2-76, TRH 1-23, and TRH 1-163. From these, YP 1-44, TRH 1-163, and TRH 1-23 showed reproducible and dose-responsive inhibition of IA-rhodamine labeling of RNF4 **(Fig. 1D, Fig. S1)**. Based on corresponding silver staining of RNF4 in these experiments, we found that TRH 1-163 may be causing protein precipitation. Based on gel-based ABPP analysis of general cysteine-reactivity in 231MFP lysates, YP 1-44 was much less selective compared to TRH 1-23 **(Fig. S1)**. Thus, TRH 1-23 appeared to be the most promising RNF4 hit **(Fig. 1D)**.

We next sought to identify the site-of-modification of TRH 1-23 within RNF4. We performed liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of tryptic digests from TRH 1-23-treated RNF4 pure protein and found that TRH 1-23 covalently modified either, but not both, of the two zinc-coordinating cysteines C132 and C135 in the RING domain of RNF4 **(Fig. 2A, 2B)**. In support of its utility as a functional RNF4 recruiter, we wanted to see if TRH 1-23 had any effect upon RNF4 autoubiquitination activity, since previous studies had shown that mutation of these cysteines to serines inhibits RNF4 function [21–23]. Surprisingly, TRH 1-23 treatment does not inhibit RNF4 autoubiquitination activity in an *in vitro* reconstituted assay **(Fig. 2C)**.

While a promising non-functional ligand against RNF4, TRH 1-23 did not show sufficient potency to be useful as an RNF4 recruiter. We thus synthesized several TRH 1-23 analogs and used gel-based ABPP to test their potency and structure-activity relationships against RNF4 **(Fig. 3A).** Among these analogs, we found CCW 16, with an *N*-benzyl and 4-methoxyphenoxyphenyl substitution on the chloroacetamide scaffold, to be among the most potent of the analogs with inhibition of IA-rhodamine labeling of RNF4 observed down to 1 μM. Further confirmatory studies revealed a CCW 16 50 % inhibitory concentration (IC50) of 1.8 μM **(Fig. 3B)**.

To better understand how CCW 16 was interacting with RNF4, we carried out covalent docking on CCW 16 bound to either C132 or C135 on a publicly available crystal structure of RNF4 **(Fig. 3C)**. In this model, CCW 16 covalent binding to C132 causes the residue to flip out. The CCW 16 ligand occupies a groove on the RNF4 surface consisting of side-chains R125, T129, and S131, with no obvious polar interactions between the ligands and the protein in this model. Interestingly, CCW 16 does not bind directly in the zinc-binding site, leaving the other three zinc-coordinating cysteines (C135, C159, and C162) unperturbed (**Fig. 3C**). In modeling CCW 16 covalently bound to C135, we observed binding on a surface groove of RNF4 occupying a region between Q161, S166, and P174. To accommodate the ligand, a dihedral rotation of Cα &

Cβ of C132 is predicted **(Fig. 3C)**. Both models indicate that zinc may still be bound by the three remaining cysteines in the site, while CCW 16 binds outside of the zinc-coordinating site. Since CCW 16 and TRH 1-23 are based on the same scaffold, these results may explain why TRH 1-23 did not inhibit RNF4 autoubiquitination activity.

Based on the structure-activity relationships observed with TRH 1-23 analogs, we thought that the 4-methoxy group on CCW16 would be an ideal position for extending a linker to yield a RNF4-based degrader. To demonstrate that we could use CCW 16 as a potential RNF4 recruiter for targeted protein degradation applications, we synthesized CCW 28-3, a bifunctional degrader linking CCW16 to the BET bromodomain family inhibitor JQ1 **(Fig. 4A)**. CCW-28-3 was prepared in five steps from commercially available materials. Demethylation of 4-(4-methoxyphenoxy)aniline yielded 4-(4-aminophenoxy)phenol, which underwent reductive amination with benzaldehyde using sodium triacetoxyborohydride as the reducing agent to form CCW 22. Alkylation of phenolic moiety of CCW 22 with 4-(Boc-amino)butyl bromide and subsequent reaction with 2-choloracetyl chloride allowed functionalization of the RNF4 recruiter with a linker containing a "latent" reactive handle, a Boc-protected amino group. Boc deprotection by trifluoroacetic acid restored the functional primary amine which could then be reacted with the BRD4-targeting JQ1 through amide coupling, yielding the bifunctional degrader CCW-28-3 as the final product. It is noteworthy that amide coupling reaction should be highly versatile and thus this synthetic scheme should be applicable for conjugating different protein-targeting ligands with carboxylic acid moiety onto our RNF4 recruiter.

CCW 28-3 showed higher potency for RNF4 than CCW16 with an IC50 of 0.54 μM **(Fig. 4B)**. Compellingly, treatment with CCW 28-3 degraded BRD4 in a dose-responsive manner in 231MFP breast cancer cells **(Fig. 4C).** We also confirmed that CCW 28-3 did not inhibit RNF4 autoubiquitination activity **(Fig. 4D)**. CCW 28-3-mediated degradation of BRD4 was prevented by pre-treatment of cells with the proteasome inhibitor bortezomib (BTZ), JQ1 alone, as well as the E1 ubiquitin activating enzyme inhibitor TAK-243 **(Fig. 4E-4F)**.

We next used isotopic tandem orthogonal proteolysis-enabled ABPP (isoTOP-ABPP) platforms to assess the proteome-wide selectivity of CCW 28-3 [4,6,7,12] **(Fig. S2; Table S2)**. We treated 231MFP cells with vehicle or CCW 28-3 and labeled the resulting proteomes with the cysteine-reactive *N*-hex-5-ynyl-2-iodo-acetamide (IA-alkyne) probe, followed by appendage of isotopically light or heavy TEV protease-cleavable

biotin-azide tags onto probe-labeled proteins in vehicle and CCW-28-3-treated groups, respectively. Probe-modified peptides were enriched and eluted and analyzed using previously described methods for isoTOP-ABPP [4,6,7,12]. While we were not able to observe the probe-modified peptide for RNF4 in this experiment likely due to its low abundance compared to other IA-alkyne labeled proteins, we demonstrated that there were only 7 potential off-targets of CCW 28-3 that showed isotopically light to heavy ratios greater than 4, out of 1114 total quantified probe-modified peptides identified. This ratio >4 indicates that the covalent ligand displaced IA-alkyne probe labeling at the particular site within the protein by >75 %. Most notably, none of these off-targets of CCW 28-3 are part of the ubiquitin-proteasome system indicating that the observed BRD4 degradation can likely be attributed to RNF4-based ubiquitination **(Fig. S2; Table S2).**

Because CCW 28-3 was not completely selective and we were targeting conserved zinc-coordinating cysteines across the RING family of E3 ligases, we next confirmed the contributions of RNF4 to CCW 28-3-mediated degradation of BRD4. We compared CCW 28-3-mediated BRD4 degradation in wild-type (WT) and RNF4 knockout (KO) HeLa cells. Convincingly, CCW 28-3-mediated degradation of BRD4 observed in HeLa WT cells was not evident in RNF4 KO cells **(Fig. 4G; Fig. S3)**. These data further support our claim that CCW 28-3 degrades BRD4 through RNF4 recruitment.

Our study demonstrates the feasibility of using ABPP-based covalent ligand screening approaches to rapidly discover chemical entry points for targeting E3 ligases and that these covalent ligand hits can be identified, optimized, and incorporated into degraders for targeted protein degradation applications. While CCW16 and CCW-28-3 are not yet completely selective for RNF4 in cells, we demonstrate that we can still degrade BRD4 in an RNF4-dependent manner. We note that CCW 28-3 does not degrade BRD4 as well as other previously reported BRD4 degraders such as MZ1 that utilizes a VHL-recruiter linked to JQ1[24]. Future medicinal chemistry efforts can be employed to optimize the potency and selectivity of CCW16 for RNF4 and to optimize linker positioning and composition of CCW 28-3 to promote better degradation of protein substrates. Nonetheless, CCW16 represents a novel, small-molecule E3 ligase recruiter for RNF4, beyond the four other E3 ligase recruiters that have been reported previously, targeting cereblon, VHL, MDM2, and cIAP [2]. We believe that the approaches described here can be utilized for future applications in expanding the scope of E3 ligase recruiters or modulators.

Methods

Covalent Ligand Library used in Initial Screen

The synthesis and characterization of many of the covalent ligands screened against RNF4 have been previously reported [4–6,13]. Synthesis of TRH 1-156, TRH 1-160, TRH 1-167, YP 1-16, YP 1-22, YP 1-26, YP 1-31, YP 1-44 have been previously reported [25–32]. The synthesis and characterization of covalent ligands that have not been reported are described in **Supporting Information.**

Gel-Based ABPP

Gel-based ABPP methods were performed as previously described [5,6,33,34]. Pure recombinant human RNF4 was purchased from Boston Biochem (K-220). RNF4 (0.25 µg) was diluted into 50 µL of PBS and 1µL of either DMSO (vehicle) or covalently acting small molecule to achieve the desired concentration. After 30 minutes at room temperature, the samples were treated with 250 nM IA-Rhodamine (Setareh Biotech, 6222, prepared in anhydrous DMSO) for 1 h at room temperature. Samples were then diluted with 20 µL of 4x reducing Laemmli SDS sample loading buffer (Alfa Aesar) and heated at 90 °C for 5 min. The samples were separated on precast 4-20% Criterion TGX gels (Bio-Rad Laboratories, Inc.). Fluorescent imaging was performed on a ChemiDoc MP (Bio-Rad Laboratories, Inc) inhibition of target labeling was assessed by densitometry using ImageJ.

LC-MS/MS analysis of RNF4

Purified RNF4 (10 µg) was diluted into 80 µL of PBS and treated for 30 min with DMSO or compound (50 µM). The DMSO control was then treated with light iodoacetamide (IA) while the compound treated sample was incubated with heavy IA for 1 h each at room temperature (100 µM, Sigma-Aldrich, 721328). The samples were precipitated by additional of 20 µL of 100% (w/v) TCA and combined pairwise before cooling to -80 C for one hour. The combined sample was then spun for at max speed for 20 min at 4 °C, supernatant is carefully removed and the sample is washed with ice cold 0.01 M HCl/90 % acetone solution. The sample was then resuspended in 2.4 M urea containing 0.1 % Protease Max (Promega Corp. V2071) in 100 mM ammonium bicarbonate buffer. The samples were reduced with 10 mM TCEP at 60 °C for 30 min. The samples were then diluted 50% with PBS before sequencing grade trypsin (1 ug per sample, Promega Corp, V5111) was added

for an overnight incubation at 37 °C. The next day the sample was centrifuged at 13200 rpm for 30 min. The supernatant was transferred to a new tube and acidified to a final concentration of 5 % formic acid and stored at -80 ^{o}C until MS analysis.

RNF4 ubiquitination assay

For *in vitro* auto-ubiquitination assay, 200 nM RNF4 in 15 µL ubiquitination assay buffer (50 mM Tris, 150mM NaCl, 5 mM $MgCl_2$, 5mM DTT, pH 7.4) was pre-incubated with DMSO vehicle or the covalently-acting compound for 30 min at room temperature. Subsequently, UBE1 (50 nM, Boston Biochem, E-305), UBE2D1 (400nM Boston Bichem, E2-615), Flag-ubiquitin (4000 nM, Boston Biochem, U-120) and ATP (200 µM) were added in ubiquitination assay buffer bring the total volume to 30 µL. The mixture was incubated at RT for 30 min before quenching with 10 µL of 4x Laemmli's buffer. Ubiquitination activity was measured by separation on an SDS-PAGE gel and western blotting as previously described.

Synthetic Methods and Characterization of Covalent Ligand Analogs and CCW 28-3 Degrader

Synthetic methods and characterization are detailed in Supporting Information

Covalent Docking of CCW 16 in RNF4

For covalent docking, a crystal structure of human RNF4 (pdb code: 4PPE) was used [35]. This crystal structure was then prepared for docking utilizing Schrödinger's Maestro (2018-1) protein preparation [36]. Missing loops and side chains were added using PRIME and only A chain was utilized for docking purposes. Protonation was carried out to optimize H-bond assignments (assuming pH 7.0) and all waters were removed. A restrained minimization (<0.3Å) was then carried out to optimize the protein. A Zn coordinated by C132, C135, C159 & C162 was removed for docking purposes.

Prior to docking, CCW16 was prepared via LigPrep. To carry out covalent docking using Schrödinger's covalent docking [37], either C132 or C135 were defined as the center of the binding grid (within 20A). CCW 16 was selected as the ligand and the appropriate reactive residues were selected. A "nucleophilic substitution" was selected as the reaction type within the covalent docking menu and calculations were carried out on a Linux workstation with Intel Xeon 2.4GHz processors running Red Hat 6.8 with 128GB memory.

Cell Culture

The 231MFP cells were obtained from Prof. Benjamin Cravatt and were generated from explanted tumor xenografts of MDA-MB-231 cells as previously described[38]. RNF4 knockout HeLa cells were purchased from EdiGene USA (CL0033025003A). RNF4 wild-type HeLa cells were provided by EdiGene USA or the UC Berkeley Cell Culture Facility. 231MFP cells were cultured in L-15 media (Corning) containing 10% (v/v) fetal bovine serum (FBS) and maintained at 37°C with 0% CO_2. HeLa cells were cultured in DMEM media (Corning) containing 10% (v/v) fetal bovine serum (FBS) and maintained at 37°C with 5% CO_2.

Cell based degrader assays

For assaying degrader activity, cells were seeded (500,000 for 231MFP cells, 300,000 for HeLa cells) into a 6 cm tissue culture dish (Corning) in 2.0 – 2.5 mL of media and allowed to adhere overnight. The following morning, media was replaced with complete media containing the desired concentration of compound diluted from a 1000x stock in DMSO. At the specified timepoint, cells were washed once with PBS on ice, before 150uL of lysis buffer was added to the plate (10 mM sodium phosphate, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X100). The cells were incubated in lysis buffer for 5 min before scraping and transfer to microcentrifuge tubes. The lysates were then frozen at -80C or immediately processed for western blotting. To prepare for western blotting, the lysates were cleared with 20,000 g spin for 10 min and the resulting supernatants quantified via BCA assay. The lysates were normalized by dilution with PBS to match the lowest concentration lysate and appropriate amount of 4x Laemmli's reducing buffer added.

Western blotting

Antibodies to RNF4 (Proteintech, 17810-1-AP, 1:1000), GAPDH (Proteintech, 60004-1-IG, 1:5000), BRD4 (Abcam, Ab128874, 1:1000), and beta-actin (Proteintech Group Inc., 6609-1-IG, 1:7000) were obtained from the specified commercial sources and dilutions were prepared in 5% BSA/TBST at the specified dilutions. Proteins were resolved by SDS/PAGE and transferred to nitrocellulose membranes using the iBlot system (Invitrogen). Blots were blocked with 5 % BSA in Tris-buffered saline containing Tween 20 (TBST) solution for 1 h at room temperature, washed in TBST, and probed with primary antibody diluted in recommended diluent

per manufacturer overnight at 4 °C. Following washes with TBST, the blots were incubated in the dark with secondary antibodies purchased from Ly-Cor and used at 1:10,000 dilution in 5 % BSA in TBST at room temperature. Blots were visualized using an Odyssey Li-Cor scanner after additional washes. If additional primary antibody incubations were required the membrane was stripped using ReBlot Plus Strong Antibody Stripping Solution (EMD Millipore, 2504), washed and blocked again before being re-incubated with primary antibody.

IsoTOP-ABPP chemoproteomic studies

IsoTOP-ABPP studies were done as previously reported [4,6,7,12]. Briefly, cells were lysed by probe sonication in PBS and protein concentrations were measured by BCA assay [39]. For *in situ* experiments, cells were treated for 90 min with either DMSO vehicle or covalently-acting small molecule (from 1000X DMSO stock) before cell collection and lysis. For *in vitro* experiments, proteome samples diluted in PBS (4 mg of proteome per biological replicate) were treated with a DMSO vehicle or covalently-acting small molecule for 30 min at room temperature. Proteomes were subsequently treated with IA-alkyne (100 µM, Chess GmbH, 3187) for 1 h at RT. CuAAC was performed by sequential addition of tris(2-carboxyethyl)phosphine (TCEP) (1 mM, Sigma), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) (34 µM, Sigma), copper (II) sulfate (1 mM, Sigma), and biotin-linker-azide—the linker functionalized with a TEV protease recognition sequence as well as an isotopically light or heavy valine for treatment of control or treated proteome, respectively. After CuAAC, proteomes were precipitated by centrifugation at 6500 x g, washed in ice-cold methanol, combined in a 1:1 control/treated ratio, washed again, then denatured and resolubilized by heating in 1.2 % SDS/PBS to 80°C for 5 minutes. Insoluble components were precipitated by centrifugation at 6500 x g and soluble proteome was diluted in 5 ml 0.2% SDS/PBS. Labeled proteins were bound to avidin-agarose beads (170 µl resuspended beads/sample, Thermo Pierce) while rotating overnight at 4°C. Bead-linked proteins were enriched by washing three times each in PBS and water, then resuspended in 6 M urea/PBS (Sigma) and reduced in TCEP (1 mM, Sigma), alkylated with iodoacetamide (IA) (18 mM, Sigma), then washed and resuspended in 2 M urea and trypsinized overnight with 2 ug/sample sequencing grade trypsin (Promega). Tryptic peptides were eluted off. Beads were washed three times each in PBS and water, washed in TEV buffer solution (water, TEV buffer,

100 μM dithiothreitol) and resuspended in buffer with Ac-TEV protease (Invitrogen) and incubated overnight. Peptides were diluted in water and acidified with formic acid (1.2 M, Spectrum) and prepared for analysis.

Mass Spectrometry Analysis

Peptides from all chemoproteomic experiments were pressure-loaded onto a 250 μm inner diameter fused silica capillary tubing packed with 4 cm of Aqua C18 reverse-phase resin (Phenomenex # 04A-4299) which was previously equilibrated on an Agilent 600 series HPLC using gradient from 100% buffer A to 100% buffer B over 10 min, followed by a 5 min wash with 100% buffer B and a 5 min wash with 100% buffer A. The samples were then attached using a MicroTee PEEK 360 μm fitting (Thermo Fisher Scientific #p-888) to a 13 cm laser pulled column packed with 10 cm Aqua C18 reverse-phase resin and 3 cm of strong-cation exchange resin for isoTOP-ABPP studies. Samples were analyzed using an Q Exactive Plus mass spectrometer (Thermo Fisher Scientific) using a 5-step Multidimensional Protein Identification Technology (MudPIT) program, using 0 %, 25 %, 50 %, 80 %, and 100 % salt bumps of 500 mM aqueous ammonium acetate and using a gradient of 5-55 % buffer B in buffer A (buffer A: 95:5 water:acetonitrile, 0.1 % formic acid; buffer B 80:20 acetonitrile:water, 0.1 % formic acid). Data was collected in data-dependent acquisition mode with dynamic exclusion enabled (60 s). One full MS (MS1) scan (400-1800 m/z) was followed by 15 MS2 scans (ITMS) of the nth most abundant ions. Heated capillary temperature was set to 200 °C and the nanospray voltage was set to 2.75 kV.

Data was extracted in the form of MS1 and MS2 files using Raw Extractor 1.9.9.2 (Scripps Research Institute) and searched against the Uniprot human database using ProLuCID search methodology in IP2 v.3 (Integrated Proteomics Applications, Inc) [40]. Cysteine residues were searched with a static modification for carboxyaminomethylation (+57.02146) and up to three differential modifications for methionine oxidation and either the light or heavy TEV tags (+464.28596 or +470.29977, respectively). Peptides were required to have at least one tryptic end and to contain the TEV modification. ProLUCID data was filtered through DTASelect to achieve a peptide false-positive rate below 5%. Only those probe-modified peptides that were evident across all two out of three biological replicates were interpreted for their isotopic light to heavy ratios. Those probe-modified peptides that showed ratios >3 were further analyzed as potential targets of the covalently-acting small-molecule. For modified peptides with ratios >3, we filtered these hits for peptides were present in all

three biological replicates. For those probe-modified peptide ratios >3, only those peptides with 3 ratios >3 were interpreted, and otherwise replaced with the lowest ratio. For those probe-modified peptide ratios >4, only those peptides with 3 ratios >4 were interpreted, and otherwise replaced with the lowest ratio. MS1 peak shapes of any resulting probe-modified peptides with ratios >3 were then manually confirmed to be of good quality for interpreted peptides across all biological replicates.

Acknowledgements

We thank the members of the Nomura Research Group and Novartis Institutes for BioMedical Research for critical reading of the manuscript. This work was supported by Novartis Institutes for BioMedical Research and the Novartis-Berkeley Center for Proteomics and Chemistry Technologies (NB-CPACT) for all listed authors. This work was also supported by grants from the National Institutes of Health (F31CA225173 for CCW).

References

(1) Burslem, G. M.; Crews, C. M. Small-Molecule Modulation of Protein Homeostasis. *Chem. Rev.* **2017**, *117* (17), 11269–11301.
(2) Lai, A. C.; Crews, C. M. Induced Protein Degradation: An Emerging Drug Discovery Paradigm. *Nat. Rev. Drug Discov.* **2017**, *16* (2), 101–114.
(3) Rape, M. Ubiquitylation at the Crossroads of Development and Disease. *Nat. Rev. Mol. Cell Biol.* **2018**, *19* (1), 59–70.
(4) Grossman, E. A.; Ward, C. C.; Spradlin, J. N.; Bateman, L. A.; Huffman, T. R.; Miyamoto, D. K.; Kleinman, J. I.; Nomura, D. K. Covalent Ligand Discovery against Druggable Hotspots Targeted by Anti-Cancer Natural Products. *Cell Chem. Biol.* **2017**, *24* (11), 1368-1376.e4.
(5) Counihan, J. L.; Wiggenhorn, A. L.; Anderson, K. E.; Nomura, D. K. Chemoproteomics-Enabled Covalent Ligand Screening Reveals ALDH3A1 as a Lung Cancer Therapy Target. *ACS Chem. Biol.* **2018**.
(6) Bateman, L. A.; Nguyen, T. B.; Roberts, A. M.; Miyamoto, D. K.; Ku, W.-M.; Huffman, T. R.; Petri, Y.; Heslin, M. J.; Contreras, C. M.; Skibola, C. F.; et al. Chemoproteomics-Enabled Covalent Ligand Screen Reveals a Cysteine Hotspot in Reticulon 4 That Impairs ER Morphology and Cancer Pathogenicity. *Chem. Commun. Camb. Engl.* **2017**, *53* (53), 7234–7237.
(7) Backus, K. M.; Correia, B. E.; Lum, K. M.; Forli, S.; Horning, B. D.; González-Páez, G. E.; Chatterjee, S.; Lanning, B. R.; Teijaro, J. R.; Olson, A. J.; et al. Proteome-Wide Covalent Ligand Discovery in Native Biological Systems. *Nature* **2016**, *534* (7608), 570–574.
(8) Wang, C.; Weerapana, E.; Blewett, M. M.; Cravatt, B. F. A Chemoproteomic Platform to Quantitatively Map Targets of Lipid-Derived Electrophiles. *Nat. Methods* **2014**, *11* (1), 79–85.
(9) Hacker, S. M.; Backus, K. M.; Lazear, M. R.; Forli, S.; Correia, B. E.; Cravatt, B. F. Global Profiling of Lysine Reactivity and Ligandability in the Human Proteome. *Nat. Chem.* **2017**, *9* (12), 1181–1190.
(10) Backus, K. M. Applications of Reactive Cysteine Profiling. *Curr. Top. Microbiol. Immunol.* **2018**.
(11) Liu, Y.; Patricelli, M. P.; Cravatt, B. F. Activity-Based Protein Profiling: The Serine Hydrolases. *Proc. Natl. Acad. Sci. U. S. A.* **1999**, *96* (26), 14694–14699.
(12) Weerapana, E.; Wang, C.; Simon, G. M.; Richter, F.; Khare, S.; Dillon, M. B. D.; Bachovchin, D. A.; Mowen, K.; Baker, D.; Cravatt, B. F. Quantitative Reactivity Profiling Predicts Functional Cysteines in Proteomes. *Nature* **2010**, *468* (7325), 790–795.

(13) Roberts, A. M.; Miyamoto, D. K.; Huffman, T. R.; Bateman, L. A.; Ives, A. N.; Akopian, D.; Heslin, M. J.; Contreras, C. M.; Rape, M.; Skibola, C. F.; et al. Chemoproteomic Screening of Covalent Ligands Reveals UBA5 As a Novel Pancreatic Cancer Target. *ACS Chem. Biol.* **2017**, *12* (4), 899–904.
(14) Wang, C.; Weerapana, E.; Blewett, M. M.; Cravatt, B. F. A Chemoproteomic Platform to Quantitatively Map Targets of Lipid-Derived Electrophiles. *Nat. Methods* **2014**, *11* (1), 79–85.
(15) Anderson, K. E.; To, M.; Olzmann, J. A.; Nomura, D. K. Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity. *ACS Chem. Biol.* **2017**, *12* (10), 2522–2528.
(16) Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; et al. In Vivo Activation of the P53 Pathway by Small-Molecule Antagonists of MDM2. *Science* **2004**, *303* (5659), 844–848.
(17) Schneekloth, A. R.; Pucheault, M.; Tae, H. S.; Crews, C. M. Targeted Intracellular Protein Degradation Induced by a Small Molecule: En Route to Chemical Proteomics. *Bioorg. Med. Chem. Lett.* **2008**, *18* (22), 5904–5908.
(18) Malecka, K. A.; Fera, D.; Schultz, D. C.; Hodawadekar, S.; Reichman, M.; Donover, P. S.; Murphy, M. E.; Marmorstein, R. Identification and Characterization of Small Molecule Human Papillomavirus E6 Inhibitors. *ACS Chem. Biol.* **2014**, *9* (7), 1603–1612.
(19) Staudinger, J. L. The Molecular Interface Between the SUMO and Ubiquitin Systems. *Adv. Exp. Med. Biol.* **2017**, *963*, 99–110.
(20) Sriramachandran, A. M.; Dohmen, R. J. SUMO-Targeted Ubiquitin Ligases. *Biochim. Biophys. Acta* **2014**, *1843* (1), 75–85.
(21) Tan, B.; Mu, R.; Chang, Y.; Wang, Y.-B.; Wu, M.; Tu, H.-Q.; Zhang, Y.-C.; Guo, S.-S.; Qin, X.-H.; Li, T.; et al. RNF4 Negatively Regulates NF-KB Signaling by down-Regulating TAB2. *FEBS Lett.* **2015**, *589* (19 Pt B), 2850–2858.
(22) Fryrear, K. A.; Guo, X.; Kerscher, O.; Semmes, O. J. The Sumo-Targeted Ubiquitin Ligase RNF4 Regulates the Localization and Function of the HTLV-1 Oncoprotein Tax. *Blood* **2012**, *119* (5), 1173–1181.
(23) Bilodeau, S.; Caron, V.; Gagnon, J.; Kuftedjian, A.; Tremblay, A. A CK2-RNF4 Interplay Coordinates Non-Canonical SUMOylation and Degradation of Nuclear Receptor FXR. *J. Mol. Cell Biol.* **2017**, *9* (3), 195–208.
(24) Zengerle, M.; Chan, K.-H.; Ciulli, A. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. *ACS Chem. Biol.* **2015**, *10* (8), 1770–1777.
(25) Kokosza, K.; Balzarini, J.; Piotrowska, D. G. Novel 5-Arylcarbamoyl-2-Methylisoxazolidin-3-Yl-3-Phosphonates as Nucleotide Analogues. *Nucleosides Nucleotides Nucleic Acids* **2014**, *33* (8), 552–582.
(26) Talaty, E. R.; Young, S. M.; Dain, R. P.; Stipdonk, M. J. V. A Study of Fragmentation of Protonated Amides of Some Acylated Amino Acids by Tandem Mass Spectrometry: Observation of an Unusual Nitrilium Ion. *Rapid Commun. Mass Spectrom.* **2011**, *25* (9), 1119–1129.
(27) Timokhin, V. I.; Gastaldi, S.; Bertrand, M. P.; Chatgilialoglu, C. Rate Constants for the β-Elimination of Tosyl Radical from a Variety of Substituted Carbon-Centered Radicals. *J. Org. Chem.* **2003**, *68* (9), 3532–3537.
(28) Cee, V. J.; Volak, L. P.; Chen, Y.; Bartberger, M. D.; Tegley, C.; Arvedson, T.; McCarter, J.; Tasker, A. S.; Fotsch, C. Systematic Study of the Glutathione (GSH) Reactivity of N-Arylacrylamides: 1. Effects of Aryl Substitution. *J. Med. Chem.* **2015**, *58* (23), 9171–9178.
(29) Le Sann, C.; Huddleston, J.; Mann, J. Synthesis and Preliminary Evaluation of Novel Analogues of Quindolines as Potential Stabilisers of Telomeric G-Quadruplex DNA. *Tetrahedron* **2007**, *63* (52), 12903–12911.
(30) Ikoma, M.; Oikawa, M.; Sasaki, M. Synthesis and Domino Metathesis of Functionalized 7-Oxanorbornene Analogs toward Cis-Fused Heterocycles. *Tetrahedron* **2008**, *64* (12), 2740–2749.
(31) Cho, S.-D.; Park, Y.-D.; Kim, J.-J.; Lee, S.-G.; Ma, C.; Song, S.-Y.; Joo, W.-H.; Falck, J. R.; Shiro, M.; Shin, D.-S.; et al. A One-Pot Synthesis of Pyrido[2,3-b][1,4]Oxazin-2-Ones. *J. Org. Chem.* **2003**, *68* (20), 7918–7920.
(32) Magolan, J.; Carson, C. A.; Kerr, M. A. Total Synthesis of (±)-Mersicarpine. *Org. Lett.* **2008**, *10* (7), 1437–1440.
(33) Louie, S. M.; Grossman, E. A.; Crawford, L. A.; Ding, L.; Camarda, R.; Huffman, T. R.; Miyamoto, D. K.; Goga, A.; Weerapana, E.; Nomura, D. K. GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity. *Cell Chem. Biol.* **2016**, *23* (5), 567–578.

(34) Medina-Cleghorn, D.; Bateman, L. A.; Ford, B.; Heslin, A.; Fisher, K. J.; Dalvie, E. D.; Nomura, D. K. Mapping Proteome-Wide Targets of Environmental Chemicals Using Reactivity-Based Chemoproteomic Platforms. *Chem. Biol.* **2015**, *22* (10), 1394–1405.

(35) Groocock, L. M.; Nie, M.; Prudden, J.; Moiani, D.; Wang, T.; Cheltsov, A.; Rambo, R. P.; Arvai, A. S.; Hitomi, C.; Tainer, J. A.; et al. RNF4 Interacts with Both SUMO and Nucleosomes to Promote the DNA Damage Response. *EMBO Rep.* **2014**, *15* (5), 601–608.

(36) *Schrödinger Release 2018-1: Maestro, Schrödinger, LLC, New York, NY, 2018.*

(37) Zhu, K.; Borrelli, K. W.; Greenwood, J. R.; Day, T.; Abel, R.; Farid, R. S.; Harder, E. Docking Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring. *J. Chem. Inf. Model.* **2014**, *54* (7), 1932–1940.

(38) Jessani, N.; Humphrey, M.; McDonald, W. H.; Niessen, S.; Masuda, K.; Gangadharan, B.; Yates, J. R.; Mueller, B. M.; Cravatt, B. F. Carcinoma and Stromal Enzyme Activity Profiles Associated with Breast Tumor Growth in Vivo. *Proc. Natl. Acad. Sci. U. S. A.* **2004**, *101* (38), 13756–13761.

(39) Smith, P. K.; Krohn, R. I.; Hermanson, G. T.; Mallia, A. K.; Gartner, F. H.; Provenzano, M. D.; Fujimoto, E. K.; Goeke, N. M.; Olson, B. J.; Klenk, D. C. Measurement of Protein Using Bicinchoninic Acid. *Anal. Biochem.* **1985**, *150* (1), 76–85.

(40) Xu, T.; Park, S. K.; Venable, J. D.; Wohlschlegel, J. A.; Diedrich, J. K.; Cociorva, D.; Lu, B.; Liao, L.; Hewel, J.; Han, X.; et al. ProLuCID: An Improved SEQUEST-like Algorithm with Enhanced Sensitivity and Specificity. *J. Proteomics* **2015**, *129*, 16–24.

Figure Legends

Figure 1. Covalent ligand screen against RNF4 using gel-based ABPP. (A) Gel-based ABPP labeling of E3 ligases MDM2, RNF4, and UBE3A. Pure protein was labeled with IA-rhodamine (IA-Rh) for 30 min at room temperature, followed by SDS/PAGE and visualization by in-gel fluorescence. **(B)** Schematic of gel-based ABPP screen of covalent ligands (50 μM) against IA-rhodamine labeling of pure RNF4, looking for compounds that inhibit probe labeling resulting in loss of fluorescence. **(C)** Gel-based ABPP screen of cysteine-reactive covalent ligands against IA-rhodamine labeling of RNF4. Covalent ligands were pre-incubated with pure RNF4 protein for 30 min prior to IA-rhodamine labeling (250 nM) for 1 h. Proteins were subjected to SDS/PAGE and visualized by in-gel fluorescence. Highlighted in red were potential hits from this screen. **(D)** Chemical structures and gel-based ABPP confirmation of reproducible RNF4 screening hits, performed as described in **(C)**. Gels were also silver stained.

Figure 2. TRH 1-23 reacts non-functionally with zinc-coordinating cysteines in RNF4. (A) LC-MS/MS analysis of TRH 1-23 covalent adduct on RNF4. RNF4 was incubated with TRH 1-23 (50 μM) for 30 min at RT. RNF4 was digested with trypsin and tryptic digests were analyzed by LC-MS/MS and we searched for the TRH 1-23 modified adduct. Shown are the MS/MS spectra of TRH 1-23-modified C132 and C135 RNF4 tryptic peptide. Highlighted in red in the peptide sequence is the cysteine that was modified. **(B)** Schematic of TRH 1-23 reactivity with C132 or C135 of RNF4. **(C)** TRH 1-23 does not inhibit RNF4 autoubiquitination assay. RNF4 was pre-incubated with TRH 1-23 (100 μM) for 30 min at room temperature followed by addition of UBA1, E2 enzyme, and ATP for 40 min at 37 C. The reaction was quenched and subjected to SDS/PAGE and Western blotting for RNF4. Gel shown in **(C)** is a representative gel from n=3.

Figure 3. Optimizing RNF4 covalent ligands using gel-based ABPP. (A) Derivatives of TRH 1-23 were tested against IA-rhodamine labeling of RNF4 using gel-based ABPP. Silver stained gels are also shown to visualize total protein content. **(B)** CCW16 was tested against IA-rhodamine labeling of RNF4 using gel-based ABPP. For **(A)** and **(B)**, covalent ligands were pre-incubated with pure RNF4 protein for 30 min prior to IA-rhodamine labeling for 1 h. Proteins were subjected to SDS/PAGE and visualized by in-gel fluorescence. In

(B), gels were quantified by densitometry to calculate IC50 values. Gel shown in **(B)** is a representative gel from n=3. **(C)** Covalent docking of CCW 16 bound to either C132 or C135 in RNF4.

Figure 4. RNF4 recruiter-based BRD4 degrader. (A) Structure of CCW 28-3, an RNF4-recruiter-based degrader linked to BRD4 inhibitor JQ1. **(B)** Gel-based ABPP analysis of CCW 28-3 against pure human RNF4. CCW 28-3 was pre-incubated with pure RNF4 protein for 30 min prior to IA-rhodamine labeling for 1 h. Proteins were subjected to SDS/PAGE and visualized by in-gel fluorescence. Gels were quantified by densitometry to calculate IC50 values. **(C)** CCW 28-3 treatment in 231MFP breast cancer cells leads to BRD4 degradation. 231MFP breast cancer cells were treated with vehicle DMSO or CCW 28-3 for 3 h. Proteins were subjected to SDS/PAGE and Western blotting for BRD4 and GAPDH loading control. **(D)** CCW 28-3 does not inhibit RNF4 autoubiquitination assay. RNF4 was pre-incubated with CCW 28-3 (10 μM) for 30 min at room temperature followed by addition of UBA1, E2 enzyme, and ATP for 60 min at 37 C. The reaction was quenched and subjected to SDS/PAGE and Western blotting for RNF4. **(E, F)** CCW 28-3 treatment in 231MFP breast cancer cells leads to proteasome-, E1 inhibitor-, and BRD4 inhibitor-dependent BRD4 degradation. Vehicle DMSO or proteasome inhibitor bortezomib (BTZ) (10 μM), E1 inhibitor TAK-243 (10 μM), or BRD4 inhibitor JQ1 (10 μM) were pre-incubated for 30 min prior to treatment with MZ1 (1 μM) or CCW 28-3 (1 μM) for 3 h. Proteins were subjected to SDS/PAGE and Western blotting for BRD4 and actin loading control. **(G)** RNF4 wild-type and knockout Hela cells were treated with CCW 28-3 (10 μM) for 5 h and subjected to SDS/PAGE and Western blotting for BRD4, RNF4, and GAPDH. Blots in **(B-G)** were quantified by densitometry. Data in **(B-G)** are from representative gels from n=3. Bar graphs are average ± sem, n=3-5/group. Significance is expressed as *$p<0.05$ compared to vehicle-treated controls and #$p<0.05$ compared to CCW 28-3 treated groups in **(E-F)** and CCW 28-3 treated wild-type cells in **(G)**.

Figure 1



Figure 2

A

TRH 1-23 reacts with C132 and C135 of RNF4

RNF4 C132



RNF4 C135



B

TRH 1-23 reactivity with C132/135 of RNF4



C

RNF4 auto-ubiquitination activity



Figure 3



Figure 4